Our Development Pipeline

TMB-003

Topical Sitaxentan

Timber is in the preclinical stages of evaluating TMB-003 (sitaxsentan), a topical ET-A receptor antagonist for the treatment of sclerotic skin diseases. Timber expects to submit an Investigational New Drug (IND) application in 2022.

Screen Shot 2021-07-08 at 7.19.39 PM.png

If you are interested in any of Timber’s ongoing clinical research programs, please contact trials@timberpharma.com.

​